MSLN and ovarian carcinoma: For example, by simultaneously targeting the FOLR1 and MSLN antigens, which are highly expressed in ovarian cancer, tumor cell elimination significantly increased from 48% with single-target therapy to 88.75%, effectively reducing the risk of recurrence caused by antigen loss.137